Cubist Systematic Strategies LLC Purchases Shares of 4,311 Genomic Health, Inc. (GHDX)

Cubist Systematic Strategies LLC purchased a new position in shares of Genomic Health, Inc. (NASDAQ:GHDX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,311 shares of the medical research company’s stock, valued at approximately $138,000.

Several other large investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC raised its stake in Genomic Health by 37.8% in the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock valued at $199,000 after purchasing an additional 1,679 shares during the last quarter. Legal & General Group Plc raised its stake in Genomic Health by 11.4% in the 2nd quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock valued at $226,000 after purchasing an additional 710 shares during the last quarter. Jane Street Group LLC acquired a new position in Genomic Health in the 3rd quarter valued at about $227,000. Parametric Portfolio Associates LLC raised its stake in Genomic Health by 5.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after purchasing an additional 441 shares during the last quarter. Finally, Voya Investment Management LLC raised its stake in Genomic Health by 18.5% in the 2nd quarter. Voya Investment Management LLC now owns 8,622 shares of the medical research company’s stock valued at $281,000 after purchasing an additional 1,344 shares during the last quarter. 89.67% of the stock is owned by institutional investors and hedge funds.

Genomic Health, Inc. (NASDAQ GHDX) opened at $35.40 on Friday. Genomic Health, Inc. has a one year low of $26.37 and a one year high of $37.50. The company has a market cap of $1,250.53, a PE ratio of -295.00 and a beta of 0.66.

In other news, COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $35.51, for a total transaction of $177,550.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James J. Vaughn sold 1,379 shares of the business’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total value of $44,831.29. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 65,717 shares of company stock valued at $2,158,232. Corporate insiders own 46.20% of the company’s stock.

Several research analysts recently weighed in on the stock. Canaccord Genuity reissued a “buy” rating and issued a $35.00 target price on shares of Genomic Health in a research note on Wednesday, September 27th. ValuEngine downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, William Blair downgraded shares of Genomic Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $31.71.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Stock Observer and is owned by of Stock Observer. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.thestockobserver.com/2018/01/14/cubist-systematic-strategies-llc-purchases-shares-of-4311-genomic-health-inc-ghdx.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply